Targeted Strategies for Today's Evolving Markets

MissionIR Blog

NeoStem (NBS) Appoints Seasoned President and Managing Director

NeoStem Inc. develops stem cell-based therapies and has built a network of adult stem cell collection centers in the U.S. and China. The company today announced Ian Zhang, Ph.D., MBA, as its new president and managing director.

Dr. Zhang holds an MBA from the University of Chicago, Graduate School of Business and holds a Ph.D. in biotechnology from Simon Fraser University. He continued his education as a postdoctoral fellow at Yale University School of Medicine.

Dr. Zhang is focused on growth strategy and acquisitions/integrations in the biotech field, with a primary dedication to biotech growth in Asia. He has extensive experience in the biotech industry and said his position will allow him to help increase China’s stem-cell marketplace.

“I am excited to join an innovative, forward-looking company like NeoStem and be part of the team of experts to help bring advanced stem cell technologies into China and develop a business in China in a regulatory environment that is supportive of stem cells and a healthcare environment that can benefit from technologies to treat diseases using stem cell based therapy,” Dr. Zhang stated in the press release.

Dr. Zhang formerly served as head of Asia Pacific Integration at Life Technologies, where he also served on the steering committee managing the acquisition and integration of Applied BioSystems.

He is also the former head of Corporate Development (Asia Pacific) for Invitrogen, where he was responsible for growth strategy and acquisitions and integrations. Dr. Zhang also managed the acquisition and integration of BioAsia, Dynal, Zymed, and Caltech by Invitrogen.

Dr. Zhang also served as the president and general manager for Dynal Biotech (Beijing) Ltd., a wholly owned subsidiary of Invitrogen.

“Now that we have launched our business in China and are generating revenues, we are excited to add such a seasoned individual to our senior management team to lead the expansion effort,” Dr. Robin Smith, CEO and chairman of the board of NeoStem stated.

For more information visit:

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *